Leqembi is a groundbreaking drug developed to slow the progression of Alzheimer’s disease, a condition that affects millions worldwide. Approved by the U.S. Food and Drug Administration (FDA), it’s often seen as a ray of hope for patients and families battling memory loss and cognitive decline.
What Is Leqembi?
Leqembi (generic name: lecanemab) is a prescription medicine used to treat early Alzheimer’s disease.
It was developed by Eisai Co. and Biogen Inc., two major pharmaceutical companies known for their work in neurology.
Key Facts:
| Feature | Description |
|---|---|
| Brand Name | Leqembi |
| Generic Name | Lecanemab |
| Manufacturer | Eisai Co. & Biogen Inc. |
| Drug Class | Monoclonal antibody (anti-amyloid beta) |
| Approved By | U.S. FDA |
| Approved Year | 2023 |
| Usage | Early-stage Alzheimer’s disease |
| Route of Administration | Intravenous (IV) infusion |
Table of Contents
Leqembi Mechanism of Action – How Does It Work?
Leqembi is a monoclonal antibody, which means it’s designed to target and remove amyloid beta plaques — sticky protein clumps that build up in the brain and are believed to cause Alzheimer’s symptoms.
Simple Explanation:
- Alzheimer’s disease damages brain cells.
- One major reason is amyloid plaque buildup.
- Leqembi binds to these plaques and helps clear them from the brain.
- This process can slow memory loss and cognitive decline in patients at an early stage of the disease.
💡 Think of it like cleaning out “clogged brain pathways” to help the mind work better — not a cure, but a slowdown.
Leqembi FDA Approval
Leqembi was granted traditional FDA approval in July 2023, following accelerated approval earlier that year.
The approval was based on results from the CLARITY-AD clinical trial, which showed that the drug slowed cognitive decline by 27% over 18 months compared to a placebo.
Key FDA Notes:
- Approved for mild cognitive impairment or early Alzheimer’s.
- Must be used under medical supervision.
- Brain MRI scans are required before and during treatment to monitor side effects like swelling or bleeding.
Leqembi Dosage & Infusion Schedule
Leqembi is not a pill — it’s given as an intravenous (IV) infusion by a healthcare professional.
Standard Dosage:
- 10 mg per kilogram of body weight
- Given every two weeks
- Infusion time: About 1 hour
Treatment Timeline:
| Duration | Infusion Frequency | Monitoring |
|---|---|---|
| Weeks 1–52 | Every 2 weeks | Regular MRI scans |
| Year 2 onward | Ongoing evaluation | Doctor’s advice |
Patients typically receive 26 infusions per year, each closely monitored for safety.
Warnings & Precautions
Before taking Leqembi, patients must discuss their full medical history with their doctor.
Major Warnings:
- Amyloid-Related Imaging Abnormalities (ARIA)
- ARIA can cause brain swelling (edema) or small brain bleeds.
- Most cases are mild, but severe ones can occur.
- Allergic Reactions
- Symptoms include rash, dizziness, or breathing difficulty.
- MRI Monitoring Required
- Doctors perform MRI scans before treatment and during the first few months to monitor brain health.
- Not Suitable for All Patients
- Avoid in patients with bleeding disorders or those taking strong blood thinners.
Leqembi Side Effects
Like all medicines, Leqembi can cause side effects — some mild, others more serious.
Common Side Effects:
- Headache
- Confusion or dizziness
- Nausea
- Flu-like symptoms
- Swelling in the brain (ARIA-E)
- Small brain bleeds (ARIA-H)
Serious Side Effects:
- Seizures (rare)
- Vision changes
- Sudden severe headache
- Difficulty walking or speaking
If any of these occur, contact your doctor immediately.
Leqembi Cost & Insurance Coverage
The average cost of Leqembi in 2025 is estimated at around $26,500 per year (U.S. pricing).
Breakdown:
| Type | Cost Estimate |
|---|---|
| Drug price | $26,500 per year |
| Infusion service | $200–$500 per session |
| MRI monitoring | $1,000–$2,000 annually |
| Total annual cost | $30,000–$35,000 |
Insurance Note:
- Medicare (U.S.) covers Leqembi under specific conditions.
- Patients must be diagnosed with early-stage Alzheimer’s and enrolled in an approved registry.
Leqembi vs Donanemab
Both Leqembi and Donanemab are advanced Alzheimer’s drugs targeting amyloid beta, but they have differences.
| Feature | Leqembi (Lecanemab) | Donanemab |
|---|---|---|
| Manufacturer | Eisai & Biogen | Eli Lilly |
| Mechanism | Targets soluble amyloid beta | Targets deposited amyloid |
| FDA Approval | July 2023 | Expected late 2024–2025 |
| Administration | Every 2 weeks | Every 4 weeks |
| Effectiveness | Slows decline by ~27% | Slows decline by ~35% |
| Side Effects | ARIA-E/H, headaches | ARIA, infusion reactions |
| Cost | ~$26,500/year | TBD (expected similar) |
💡 Both drugs offer hope — but neither cures Alzheimer’s. They help slow progression, especially when started early.
Leqembi Effectiveness
The CLARITY-AD trial included nearly 1,800 participants. Results showed:
- 27% slower decline in memory and thinking skills.
- Less buildup of amyloid plaques (confirmed by brain scans).
- Improvements in daily activities like managing finances or remembering names.
However, some experts argue that the clinical benefits are modest compared to the high cost and potential side effects.
Leqembi Manufacturer Information
| Manufacturer | Country | Website |
|---|---|---|
| Eisai Co., Ltd. | Japan | www.eisai.com |
| Biogen Inc. | USA | www.biogen.com |
These companies jointly handle production, distribution, and post-market safety monitoring.
Who Can Take Leqembi?
Leqembi is approved only for patients with early Alzheimer’s disease who:
- Show mild cognitive impairment (MCI)
- Have confirmed amyloid buildup (via PET scan or CSF test)
- Are under regular doctor supervision
FAQs
1. What is the drug Leqembi used for?
Leqembi is used to treat early Alzheimer’s disease by removing amyloid plaques from the brain to slow memory loss.
2. Who makes Leqembi?
It is jointly manufactured by Eisai Co. (Japan) and Biogen Inc. (U.S.).
3. How much does Leqembi cost?
Around $26,500 per year, excluding infusion and monitoring costs.
4. Is Leqembi FDA-approved?
Yes. It received full FDA approval in July 2023.
5. What are the main side effects?
Headaches, swelling in the brain, confusion, and nausea.
6. Leqembi vs Donanemab – which is better?
Both show similar results, but Donanemab may work slightly faster in some patients.
7. How many infusions are required?
Two per month (every two weeks), under medical supervision.
8. Is Leqembi safe for everyone?
No. It’s not suitable for patients with severe bleeding risks or certain health conditions.
9. What’s the controversy around Leqembi?
Concerns about its high cost, modest results, and side effects have led to mixed opinions.
10. Can Leqembi cure Alzheimer’s?
No. It only slows the disease’s progression, but doesn’t cure it.
